Abstract:Chemotherapy remains the mainstay of cancer treatment, and doxorubicin (DOX) is recommended as a first-line chemotherapy drug against cancer. However, systemic adverse drug reactions and multidrug resistance limit its clinical applications. Here, a tumor-specific reactive oxygen species (ROS) self-supply enhanced cascade responsive prodrug activation nanosystem (denoted as /L) was developed to optimize multidrug resistance tumor chemotherapy efficacy while minimizing the side effects. /L was constructed by encapsulating the ROS-generating agent β-lapachone (Lap) and the ROS-responsive doxorubicin prodrug (BDOX) in acidic pH-sensitive heterogeneous nanomicelles. /L exhibited particle size decrease and charge increase when it reached the tumor microenvironment due to acid-triggered PEG detachment, to favor its endocytosis efficiency and deep tumor penetration. Furthermore, after /L internalization, rapidly released Lap was catalyzed by the overexpressed quinone oxidoreductase-1 (NQO1) enzyme NAD(P)H in tumor cells to selectively raise intracellular ROS levels. Subsequently, ROS generation further promoted the specific cascade activation of the prodrug BDOX to exert the chemotherapy effects. Simultaneously, Lap-induced ATP depletion reduced drug efflux, synergizing with increased intracellular DOX concentrations to assist in overcoming multidrug resistance. This tumor microenvironment-triggered cascade responsive prodrug activation nanosystem potentiates antitumor effects with satisfactory biosafety, breaking the chemotherapy limitation of multidrug resistance and significantly improving therapy efficiency. Statement of significance Chemotherapy remains the mainstay of cancer treatment, and doxorubicin (DOX) is recommended as a first-line chemotherapy drug against cancer. However, systemic adverse drug reactions and multidrug resistance limit its clinical applications. Here, a tumor-specific reactive oxygen species (ROS) self-supply enhanced cascade responsive prodrug activation nanosystem (denoted as /L) was developed to optimize multidrug resistance tumor chemotherapy efficacy while minimizing the side effects. The work provides a new sight for simultaneously addressing the molecular mechanisms and physio-pathological disorders to overcome MDR in cancer treatment.

Tumor-Targeted Oxaliplatin(IV) Prodrug Delivery Based on ROS-Regulated Cancer-Selective Glycan Labeling

Cancer Cell-Targeted Cisplatin Prodrug Delivery in Vivo Via Metabolic Labeling and Bioorthogonal Click Reaction

Self-controlled Release of Oxaliplatin Prodrug from D-Α-tocopheryl Polyethylene Glycol 1000 Succinate (TPGS) Functionalized Mesoporous Silica Nanoparticles for Cancer Therapy

A tumor-specific ROS self-supply enhanced cascade-responsive prodrug activation nanosystem for amplified chemotherapy against multidrug-resistant tumors

An Erythrocyte-Delivered Photoactivatable Oxaliplatin Nanoprodrug for Enhanced Antitumor Efficacy and Immune Response

Tailored Design of an ROS-Responsive Drug Release Platform for Enhanced Tumor Therapy Via “sequential Induced Activation Processes”

A Novel ROS-activable Self-Immolative Prodrug for Tumor-Specific Amplification of Oxidative Stress and Enhancing Chemotherapy of Mitoxantrone.

An Autonomous Tumor-Targeted Nanoprodrug for Reactive Oxygen Species-Activatable Dual-Cytochrome C/doxorubicin Antitumor Therapy

A pH-responsive liposomal nanoplatform for co-delivery of a Pt(IV) prodrug and cinnamaldehyde for effective tumor therapy

ROS‐Responsive Polyprodrug Nanoparticles for Triggered Drug Delivery and Effective Cancer Therapy

Reactive Oxygen Species-Activatable Camptothecin Polyprodrug Based Dextran Enhances Chemotherapy Efficacy by Damaging Mitochondria

ROS-Switchable Polymeric Nanoplatform with Stimuli-Responsive Release for Active Targeted Drug Delivery to Breast Cancer.

In-situ oxidative polymerization of platinum(IV) prodrugs in pore-confined spaces of CaCO3 nanoparticles for cancer chemoimmunotherapy

Oxygen-supplying ROS-responsive prodrug for synergistic chemotherapy and photodynamic therapy of colon cancer

ROS Triggered Cleavage of Thioketal Moiety to Dissociate Prodrug Nanoparticles for Chemotherapy.

Endogenous Reactive Oxygen Species Burst Induced and Spatiotemporally Controlled Multiple Drug Release by Traceable Nanoparticles for Enhancing Antitumor Efficacy

Tumor Permeable Self-Delivery Nanodrug Targeting Mitochondria for Enhanced Chemotherapy.

Development of A Reactive Oxygen Species (Ros)-Responsive Nanoplatform for Targeted Oral Cancer Therapy

Reactive Oxygen Species Activatable Heterodimeric Prodrug as Tumor-Selective Nanotheranostics

Activatable Mitochondria‐Targeting Organoarsenic Prodrugs for Bioenergetic Cancer Therapy

A Smart Theranostic Prodrug System Activated by Reactive Oxygen Species for Regional Chemotherapy of Metastatic Cancer.